Summary & Overview
CPT 0612U: Plasma cfDNA Methylation Assay for Liver Cancer Risk
CPT code 0612U is a Proprietary Laboratory Analyses (PLA) code reserved for the HelioHCCTMTrace assay from Helio Genomics®. The test performs high-dimensional methylation profiling of cell–free DNA from plasma across more than 1,000 genomic regions and reports an algorithm-derived quantitative measure related to liver cancer detection or risk assessment. As a PLA code, 0612U identifies a single manufacturer's proprietary laboratory test, which has implications for coding specificity, coverage determinations, and payer policy reviews nationally.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical purpose and service setting for the assay, and a national-oriented review of considerations that affect adoption and payment: benchmark practices for PLA codes, typical places of service for cfDNA-based diagnostics, and the types of documentation and clinical context payers commonly request. The publication summarizes available policy trends and benchmarking approaches relevant to proprietary molecular diagnostics without state-level detail.
This resource is intended to clarify what CPT code 0612U represents, who it applies to, and what topics stakeholders should expect when evaluating coverage or billing for a proprietary cfDNA methylation assay for liver cancer detection or risk assessment.
Billing Code Overview
CPT code 0612U is a Proprietary Laboratory Analyses (PLA) code that applies exclusively to the HelioHCCTMTrace test from Helio Genomics®. The test analyzes cell–free DNA (cfDNA) from plasma for methylation patterns across more than 1,000 genomic regions. Test results are combined into an algorithm that produces a quantitative measure related to liver cancer detection or risk assessment.
Service type: Proprietary laboratory molecular diagnostic assay (cfDNA methylation profiling) performed on plasma.
Typical site of service: Clinical laboratory or reference laboratory; sample collection occurs in outpatient phlebotomy settings or other sites where blood draws are performed.
Data not available in the input for common modifiers, associated taxonomies, ICD-10 diagnoses, related codes, and service line.
Clinical & Coding Specifications
Clinical Context
A typical patient scenario involves an adult with risk factors for hepatocellular carcinoma (HCC) such as chronic hepatitis B or C infection, cirrhosis from alcohol or nonalcoholic fatty liver disease, or a history of hepatic lesions on imaging. A hepatology or oncology clinician orders 0612U (HelioHCCTMTrace) as a blood-based molecular assay to assess cell-free DNA methylation patterns when imaging results are indeterminate, when enhanced surveillance is desired, or to provide additional risk stratification for early detection of liver cancer.
Workflow: the clinician documents the indication in the electronic health record, obtains informed consent for laboratory testing, and places a venipuncture order. A phlebotomist draws a plasma sample using required collection and handling protocols and ships it to the performing laboratory (Helio Genomics®). The lab performs cfDNA extraction, methylation analysis across >1,000 genomic regions, and applies the proprietary algorithm to produce a quantitative result. Results are returned to the ordering clinician and incorporated into the patient’s management plan (surveillance imaging interval adjustment, referral to hepatology/oncology, or additional diagnostic workup). Typical site of service is an outpatient clinic, ambulatory diagnostic center, or hospital outpatient laboratory with specimen transport to the performing central lab.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 |